Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves

ClinicalTrials.gov ID: NCT01939366

Public ClinicalTrials.gov record NCT01939366. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 4, 2026, 11:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy, Safety and Tolerability of Multiple Doses of Oral Cebranopadol in Subjects With Moderate to Severe Chronic Pain Due to Diabetic Peripheral Neuropathy.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this trial is to evaluate if cebranopadol is safe and can decrease pain in patients when compared to placebo (a tablet that does not contain active product) and when compared to a marketed product containing pregabalin (Lyrica®). Furthermore, this trial will be undertaken to find out if the patient's general health and well-being improves under trial treatment. The concentrations of cebranopadol in the blood will be investigated to get a better understanding of how it is absorbed from the gut, distributed and broken down in the body, and eliminated from the body.

Study identification

NCT ID: NCT01939366
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Tris Pharma, Inc.; Industry
Enrollment: 699 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 26, 2013
Primary completion: Dec 31, 2014
Completion: Jan 27, 2015
Last update posted: Jul 14, 2021

2013 – 2015

United States locations

U.S. sites: 15
U.S. states: 8
U.S. cities: 14

Facility	City	State	ZIP	Site status
US002	Mesa	Arizona	85215	—
US001	Garden Grove	California	92843	—
US019	Laguna Hills	California	92653	—
US014	National City	California	91950	—
US007	Orange	California	92868	—
US011	Hialeah	Florida	33012	—
US012	Miami	Florida	33135	—
US009	Orlando	Florida	32806	—
US004	Blackfoot	Idaho	83221	—
US006	Elgin	Illinois	60123	—
US016	West Long Branch	New Jersey	07764	—
US008	Brooklyn	New York	11229	—
US005	Brooklyn	New York	11235	—
US021	New York	New York	10128	—
US003	West Jordan	Utah	84088	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 67 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01939366, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 14, 2021 · Synced Sep 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01939366 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →